Cas No.: | 924416-43-3 |
Chemical Name: | AdipoRon |
Synonyms: | AdipoRon;2-(4-Benzoylphenoxy)-N-(1-benzylpiperidin-4-yl)acetamide;Acetamide, 2-(4-benzoylphenoxy)-N-[1-(phenylmethyl)-4-piperidinyl]-;SC-396658;2-(4-Benzoylphenoxy)-N-[1-(phenylmethyl)-4-piperidinyl]-acetamide;AdipoR agonist;AdipoRon hydrochloride;2-(4-Benzyoylphenoxy)-N-[1-(phenylmethyl)-4-piperidinyl]acetamidehydrochloride;2-(4-Benzyoylphenoxy)-N-[1-(phenylmethyl)-4-piperidinyl]acetamide hydrochloride;ND7UVH6GKJ;2-(4-Benzoylphenoxy)-N-[1-(phenylmethyl)-4-piperidinyl]acetamide;C27H28N2O3;Acetamide,2-(4-benzoylphenoxy)-N-[1-(phenylmethyl)-4-piperidinyl]-;2-(4-Benzoylphenoxy)-N-(1-(phenylmethyl)-4-piperidinyl)acetamide;AMPD00101;HMS3653C18;BCP08895;ZLB41643;2197AH;BDBM50059083;s7365;STL507766;AM85966;MCULE;CCG-268984;CCG-268984;CCG-268984;CCG-268984;SY103513;SY103513;SY103513;SY103513;AS-35052;AS-35052;AS-35052;AS-35052;AC-35903;AC-35903;AC-35903;AC-35903;AN-465/43506510;AN-465/43506510;AN-465/43506510;AN-465/43506510;SCHEMBL17938602;SCHEMBL17938602;SCHEMBL17938602;SCHEMBL17938602;EX-A283;EX-A283;EX-A283;EX-A283;AKOS007999700;AKOS007999700;AKOS007999700;AKOS007999700;NCGC00370758-10;NCGC00370758-10;NCGC00370758-10;NCGC00370758-10;FT-0700407;FT-0700407;FT-0700407;FT-0700407;924416-43-3;924416-43-3;924416-43-3;924416-43-3;2-(4-benzoylphenoxy)-N-(1-benzylpiperidin-4-yl)acetamide;2-(4-benzoylphenoxy)-N-(1-benzylpiperidin-4-yl)acetamide;2-(4-benzoylphenoxy)-N-(1-benzylpiperidin-4-yl)acetamide;2-(4-benzoylphenoxy)-N-(1-benzylpiperidin-4-yl)acetamide;SB17384;SB17384;SB17384;MFCD08271060;SB17384;MFCD08271060;MFCD08271060;SW219831-1;MFCD08271060;SW219831-1;EN300-80366;SW219831-1;SW219831-1;EN300-80366;Z32352521;EN300-80366;EN300-80366;Z32352521;CHEMBL3393145;Z32352521;Z32352521;CHEMBL3393145;2-(4-benzoylphenoxy)-N-(1-benzyl-4-piperidinyl)acetamide;CHEMBL3393145;CHEMBL3393145;Acetamide, 2-(4-benzoylphenoxy)-N-(1-(phenylmethyl)-4-piperidinyl)-;2-(4-benzoylphenoxy)-N-(1-benzyl-4-piperidinyl)acetamide;2-(4-benzoylphenoxy)-N-(1-benzyl-4-piperidinyl)acetamide;2-(4-benzoylphenoxy)-N-(1-benzyl-4-piperidinyl)acetamide;UNII-ND7UVH6GKJ;Acetamide, 2-(4-benzoylphenoxy)-N-(1-(phenylmethyl)-4-piperidinyl)-;Acetamide, 2-(4-benzoylphenoxy)-N-(1-(phenylmethyl)-4-piperidinyl)-;Acetamide, 2-(4-benzoylphenoxy)-N-(1-(phenylmethyl)-4-piperidinyl)-;HY-15848;UNII-ND7UVH6GKJ;UNII-ND7UVH6GKJ;UNII-ND7UVH6GKJ;HY-15848;HY-15848;HY-15848 |
SMILES: | O=C(C([H])([H])OC1C([H])=C([H])C(C(C2C([H])=C([H])C([H])=C([H])C=2[H])=O)=C([H])C=1[H])N([H])C1([H])C([H])([H])C([H])([H])N(C([H])([H])C2C([H])=C([H])C([H])=C([H])C=2[H])C([H])([H])C1([H])[H] |
Formula: | C27H28N2O3 |
M.Wt: | 428.5228 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | AdipoRon is an orally active adiponectin receptor (AdipoR) agonist, binding to AdipoR1 and AdipoR2 with Kds of 1.8 and 3.1 μM, respectively. |
In Vivo: | AdipoRon is an orally active and specific AdipoR agonist, binds to AdipoR1 and AdipoR2, with Kds of 1.8 and 3.1 μM. AdipoRon (50 nM-50 μM) increases AMPK phosphorylation via AdipoR1[1]. AdipoRon (50 μM) dose-dependently attenuates the expression of TNF-α and TGF-β1 in the L02 cells. AdipoRon exhibits significant and dosage-dependent growth suppression on macrophages[2]. AdipoRon treatment significantly improves cardiac functional recovery after reperfusion, and inhibits post-MI apoptosis[3]. AdipoRon exerts vasodilation by mechanisms distinct to adiponectin and induces vasorelaxation without a marked decrease in VSMC [Ca2+]i[4]. |
In Vitro: | AdipoRon is an orally active and specific AdipoR agonist, binds to AdipoR1 and AdipoR2, with Kds of 1.8 and 3.1 μM. AdipoRon (50 nM-50 μM) increases AMPK phosphorylation via AdipoR1[1]. AdipoRon (50 μM) dose-dependently attenuates the expression of TNF-α and TGF-β1 in the L02 cells. AdipoRon exhibits significant and dosage-dependent growth suppression on macrophages[2]. AdipoRon treatment significantly improves cardiac functional recovery after reperfusion, and inhibits post-MI apoptosis[3]. AdipoRon exerts vasodilation by mechanisms distinct to adiponectin and induces vasorelaxation without a marked decrease in VSMC [Ca2+]i[4]. |